Twist Bioscience Corporation Grants Inducements Under NASDAQ Listing Rule 5635
November 9, 2023
☀️Trending News
Twist Bioscience ($NASDAQ:TWST) Corporation, a leading synthetic biology and gene synthesis provider, has granted inducement awards in accordance with NASDAQ Listing Rule 5635. These awards have been given to newly hired employees and members of the Board of Directors as part of their employment or service agreement. The awards consist of restricted stock units and options to purchase common stock. It has developed an innovative semiconductor-based process for synthesizing DNA on silicon chips which reduces the time and cost associated with producing synthetic DNA.
Twist Bioscience is dedicated to revolutionizing the way that life sciences and healthcare companies access synthetic DNA. Its products have enabled a broad range of companies to accelerate their research and development processes by providing them with reliable, cost-effective access to specialty DNA products.
Market Price
Twist Bioscience Corporation announced on Wednesday that it was granting inducements under NASDAQ Listing Rule 5635. The stock opened at $18.2 but closed at $17.4, down 4.6% from the previous closing price of $18.2. Twist Bioscience Corporation is a San Francisco-based synthetic biology company that specializes in DNA synthesis and next-generation sequencing products for research and development. With this new inducement, it hopes to bolster its market position and generate more interest in its products. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Twist Bioscience. More…
| Total Revenues | Net Income | Net Margin |
| 235.47 | -209.49 | -88.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Twist Bioscience. More…
| Operations | Investing | Financing |
| -133.75 | -232.93 | 270.53 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Twist Bioscience. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 810.33 | 152.78 | 12.32 |
Key Ratios Snapshot
Some of the financial key ratios for Twist Bioscience are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 47.5% | – | -88.2% |
| FCF Margin | ROE | ROA |
| -89.9% | -18.4% | -16.0% |
Analysis
At GoodWhale, we analyze the wellbeing of companies to help investors make informed decisions. After running our analysis on TWIST BIOSCIENCE, we classified them as a ‘cheetah’ – a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. This type of company might interest riskier investors who are looking for fast growth but are willing to accept the reduced stability. When it comes to TWIST BIOSCIENCE specifically, our Star Chart shows they are strong in asset and growth, but relatively weak in dividend and profitability. Their intermediate health score of 4/10, considering their cashflows and debt, suggests that they are likely to safely ride out any crisis without the risk of bankruptcy. More…
Peers
It offers DNA synthesis on a silicon chip, which enables the company to offer its services at a lower cost than its competitors. The company’s competitors include HTG Molecular Diagnostics Inc, Proteome Sciences PLC, and Genedrive PLC.
– HTG Molecular Diagnostics Inc ($NASDAQ:HTGM)
FoundHTG’s cutting-edge molecular diagnostic platform and cancer test portfolio offers clinicians actionable insights to improve patient outcomes. The company’s tests are designed to guide precision cancer treatment decisions by identifying the specific genetic alterations that drive a patient’s tumor.
FoundHTG’s products are available through a global network of distributors and partners. The company’s tests are used in more than 30 countries and have been validated in over 1,000 peer-reviewed publications.
FoundHTG has a market cap of $6.07M and a ROE of -156.17%.
– Proteome Sciences PLC ($LSE:PRM)
Proteome Sciences PLC is a United Kingdom-based company, which is engaged in the business of proteomics. The Company’s primary focus is on the development and application of proteomics technologies for the biomarker discovery, validation and protein profiling across a range of life science research and clinical applications. It operates through two segments: Biomarkers and Protein Analysis. The Biomarkers segment includes the development and commercialization of biomarkers for diagnostics and drug development. The Protein Analysis segment provides contract research services to the pharmaceutical, biotechnology and academic sectors.
– Genedrive PLC ($LSE:GDR)
Genedrive PLC is a molecular diagnostics company. The Company focuses on the development and commercialization of its technology for the diagnosis of infectious diseases and point-of-care testing. It operates through the following segments: Genedrive and Genedrive Asia Pacific. The Genedrive segment comprises the Company’s operations in Europe, the Middle East, Africa and the Americas. The Genedrive Asia Pacific segment comprises the Company’s operations in Asia Pacific.
Summary
Twist Bioscience Corporation is a biotechnology company specializing in DNA synthesis and sequencing. The stock price has moved down since then. Furthermore, Twist Bioscience has recently completed multiple acquisitions and partnerships that are expected to accelerate its growth in the coming years. The company also has a strong balance sheet with adequate liquidity, making it an attractive buy for long-term investors.
However, one should also take caution given the volatile nature of the biotech market and the risk of dilution from the inducement grants. Overall, Twist Bioscience is a promising investment opportunity that could yield good returns for investors if managed properly.
Related Posts
Recent Posts
